Active substance
Metolazone
- US FDA 18
- Health Canada 1
- US price lines 3
- NHS prices 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| METOLAZONE | 5MG; 10MG | tablet · oral | SANDOZ | Prescription | 19 Dec 2003 |
| METOLAZONE | 2.5MG | tablet · oral | SANDOZ | Prescription | 19 Dec 2003 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | MYLAN | Prescription | 23 Dec 2003 |
| METOLAZONE | 10MG | tablet · oral | ROXANE | Prescription | 29 Apr 2004 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | ALEMBIC | Prescription | 2 Dec 2020 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | INNOGENIX | Prescription | 30 Mar 2021 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | UNICHEM | Prescription | 30 Mar 2021 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | RUBICON RESEARCH | Prescription | 20 Aug 2021 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | RENATA | Prescription | 24 Oct 2022 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | NE RX PHARMA | Prescription | 25 Oct 2022 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | ACERTIS PHARMS | Prescription | 17 Apr 2024 |
| ZAROXOLYN | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | I3 PHARMS | Discontinued | 27 Nov 1973 |
| DIULO | 2.5MG; 5MG; 10MG | tablet · oral | GD SEARLE LLC | Discontinued | 24 Feb 1981 |
| MYKROX | 0.5MG | tablet · oral | CHARTWELL MOLECULAR | Discontinued | 30 Oct 1987 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | ANI PHARMS | Discontinued | 24 Dec 2003 |
| METOLAZONE | 10MG | tablet · oral | ROXANE | Discontinued | 29 Apr 2004 |
| METOLAZONE | 10MG | tablet · oral | WATSON LABS | Discontinued | 21 Jul 2004 |
| METOLAZONE | 2.5MG; 5MG; 10MG | tablet · oral | MICRO LABS | Discontinued | 6 Nov 2024 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ZAROXOLYN | 00888400 | 2.5 MG | TABLET · ORAL | SANOFI-AVENTIS CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | METOLAZONE 10 MG TABLET | $0.38134 | per EA | 23 Sep 2026 |
| US NADAC | METOLAZONE 2.5 MG TABLET | $0.23282 | per EA | 23 Sep 2026 |
| US NADAC | METOLAZONE 5 MG TABLET | $0.23919 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Metolazone 5mg tablets | £110.00 | 20 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.